ClinicalTrials.gg
Not yet recruitingNCT07927374HARBORUpdated Nov 10, 2026

HistoMap AlloSure Renal Biopsies Observational Research Study

An observational study in Kidney Transplant Rejection, T-Cell Mediated Rejection and Kidney Transplantation, sponsored by CareDx. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by CareDx · Observational

Updated Nov 10, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,250
Ages
18 Years and older
Sex
All
01

Study summary

The HistoMap AlloSure Renal Biopsies Observational Research Study (HARBOR) is a prospective, multicenter, observational cohort study of adult kidney transplant recipients undergoing a clinically indicated kidney allograft biopsy. The study will collect biospecimens and associated clinical data to support the development and evaluation of molecular approaches for assessing kidney allograft rejection. It will also examine relationships among histopathology, tissue-based gene expression profiling using HistoMap, donor-derived cell-free DNA (dd-cfDNA) measured using AlloSure, and clinical outcomes. As an observational study, HARBOR will not direct clinical care, and all diagnostic and treatment decisions will remain at the discretion of the treating clinicians in accordance with standard clinical practice.

Read the detailed description

HARBOR will include enrollment of approximately 1,250 adult kidney transplant recipients undergoing clinically indicated kidney allograft biopsies at U.S. transplant centers. The study will prospectively collect blood and tissue specimens, biopsy findings, molecular test results, and associated clinical data to support research on kidney allograft rejection.

Histopathologic findings will be assessed in relation to results from HistoMap, a tissue-based gene expression profiling assay, and AlloSure, a donor-derived cell-free DNA assay. Secondary analyses will evaluate agreement among diagnostic assessments and associations with kidney allograft function and outcomes.

Participants will be classified into two observational cohorts using index-biopsy findings and AlloSure results. All participants will undergo an assessment at Month 1. Participants meeting criteria for Cohort 1 will have additional assessments at Months 3 and 6, with a final assessment at Month 12; participants in Cohort 2 will complete study follow-up at Month 1. The study will not assign or direct treatment, and all clinical management decisions will remain at the discretion of the treating clinicians according to standard of care.

02

Conditions studied

  • Kidney Transplant Rejection
  • T-Cell Mediated Rejection
  • Kidney Transplantation
  • Antibody Mediated Rejection

Keywords

  • Kidney Transplantation
  • Kidney Allograft Rejection
  • Kidney Allograft Biopsy
  • Antibody-Mediated Rejection
  • T-Cell Mediated Rejection
  • Histopathology
  • Molecular Diagnostics
  • Donor-Derived Cell-Free DNA
  • AlloSure
  • HistoMap
  • Gene Expression Profiling
  • Biomarker Development
  • Transplant Monitoring
  • Kidney Allograft Dysfunction
  • Biospecimen Repository
  • Banff Classification
  • Donor-Specific Antibodies (DSA)
03

In context

Lead sponsor

CareDx is the lead sponsor of 17 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult kidney transplant recipients with a functioning kidney allograft undergoing a clinically indicated kidney allograft biopsy at participating U.S. transplant centers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult age 18 or older at time of
  • Kidney transplant recipient with a functioning allograft
  • Undergoing an indicated per transplant center's SOC, based on any traditional metrics of function (, Serum Creatinine, proteinuria) or donor-specific antibodies (DSA) or dd-cfDNA
  • Enrolled within 14 days prior to biopsy.
  • Willing and able to provide informed consent to participate in the study.
  • Willing and able to comply with study visits and procedures, including scheduled sample collections and clinical assessments.

Exclusion criteria

Exclusion Criteria:

  • Has received a multi-organ transplant (e.g., liver-kidney, heart-kidney)
  • Pregnant at the time of enrollment.
  • Receiving kidney from patient's homozygous twin
  • Deemed by researchers to be unsuitable for clinical study, due to known medical or psychological condition(s) that might interfere with the participant's full participation in the study, pose any additional risk for the participant, or confound the assessment of study outcomes.
  • Active systemic bacterial or fungal infection within 14 days prior to .
  • Current or receiving treatment for malignancy except for non-melanoma skin cancer.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,250 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort 1

    Kidney transplant recipients with rejection or related findings identified by histopathology or HistoMap, BK nephropathy on the index biopsy, or an AlloSure dd-cfDNA result ≥0.5%. Study follow-up includes assessments at Months 1, 3, and 6 after the index biopsy and an end-of-study assessment at Month 12.

  • Cohort 2

    Kidney transplant recipients without evidence of rejection by histopathology or HistoMap, without BK nephropathy on the index biopsy, and with an AlloSure dd-cfDNA result \<0.5%. The Month 1 assessment serves as the end-of-study visit.

06

What researchers measure

Primary outcomes

  1. Number of Unique Participants Providing Repository Specimens

    Number of unique participants contributing biospecimens, summarized by specimen type and study visit.

    Time frame: Index biopsy through the last protocol-specified collection, up to Month 6 after index biopsy.

  2. Frequency and Proportion of Specimens Collected Without Nonconformities

    Frequency and proportion of specimens collected and processed according to the laboratory manual without collection or processing nonconformities.

    Time frame: Index biopsy through the last protocol-specified collection, up to Month 6 after index biopsy.

  3. Frequency and Proportion of Biopsies With Associated HistoMap, AlloSure, and Additional Streck Tube Collection

    Frequency and proportion of biopsies with associated tissue gene expression profiling (HistoMap), AlloSure testing, and at least one additional Streck blood tube collected.

    Time frame: Through study completion (up to 12 months following index biopsy).

  4. Frequency and Proportion of Participants With Each Kidney Rejection Type

    Frequency and proportion of participants classified into each kidney rejection category based on study assessments. Rejection categories will be reported separately for histopathology and HistoMap assessments.

    Time frame: Index biopsy assessment.

Secondary outcomes

  1. Clinical Performance Characteristics of HistoMap Relative to Histopathology

    Clinical performance characteristics of HistoMap for classification of kidney allograft rejection relative to histopathology in a real world setting.

    Time frame: Index biopsy assessment.

  2. Concordance of Rejection Status Across HistoMap, AlloSure, and Histopathology

    Concordance rate of rejection status among HistoMap, AlloSure, and histopathology assessments.

    Time frame: Index biopsy assessment.

  3. Association Between HistoMap Classification and Kidney Function

    Association between index-biopsy HistoMap classification (AMR, TCMR, Mixed Rejection, or No Rejection) and kidney function as measured by estimated glomerular filtration rate (eGFR).

    Time frame: Months 1, 3, and 6 post-index biopsy.

  4. Association Between HistoMap Results and Predicted Graft Survival

    Association of graft survival probabilities calculated using the iBox Prediction System across HistoMap results.

    Time frame: Predicted graft survival at 3, 5, and 7 years using assessments performed at Months 3 and 6 post-index biopsy.

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 10, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07927374
Lead sponsor
CareDx
Responsible party
Sponsor
First posted
Nov 10, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Dr. Peale Chuang, MD
Contact
pchuang@caredx.com
888-255-6627

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion